MADISON, Wis. – Voximetry Incorporated is pleased to announce the receipt of a $2 million grant from the U.S. National Cancer Institute, part of the National Institutes of Health, to enhance the efficiency and accuracy of conventional nuclear medicine SPECT/CT imaging. This marks the fifth significant NIH grant awarded to Voximetry, underscoring our leadership in advancing cancer treatment technologies.
Voximetry is at the forefront of revolutionizing cancer care through cutting-edge, AI-driven software and services powered by high-speed NVIDIA GPUs. Our automated technology has emerged as the accuracy leader in clinical trial data analysis and personalized clinical treatments. Preliminary findings from our Phase I work indicate this project could reduce the time required for a theranostic SPECT/CT scan by a 75%.
“The results from our Phase 1 work are compelling,” stated Dr. Sue Wallace, CEO of Voximetry. “Today’s theranostic centers face significant constraints due to limited scanner availability. Reducing scan times by a factor of four to increase department throughput would be really good for the clinic, and even better for the patient.”
Theranostic treatments utilize targeted pharmaceuticals combined with toxic radionuclides to selectively destroy cancer cells. With over 225 active clinical trials and 34 pharmaceutical companies investing in theranostics, early data suggests these therapies may offer superior outcomes for patients with metastatic cancer compared to traditional chemotherapy, often with better tolerance.
“So many patients need these treatments, but they must be done with safe monitoring,” said Dr. Joe Grudzinski, Chief Innovation Officer at Voximetry. “That requires post-therapy SPECT/CT imaging. We think we can help by significantly reducing the time required to collect a quality scan that can be used to safely monitor the treatments.”
The grant-supported initiative may also pave the way for future theranostic treatments, particularly those involving challenging imaging modalities such as alpha-emitters, facilitating high-quality patient monitoring that current SPECT/CT systems cannot provide.
This research will be supported by the National Cancer Institute of the National Institutes of Health under Award Number R44CA291564. This content is solely the responsibility of Voximetry and does not necessarily represent the official views of the National Institutes of Health.
ABOUT VOXIMETRY
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.
ABOUT TORCH
Torch® Dose Assessment software is a proprietary product developed by Voximetry and approved for clinical use by the FDA. Torch design and development continues to be supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA221491 and 2R44CA291564. The product is solely the responsibility of Voximetry and does not represent the official views of the National Institutes of Health.